Clinical Daily Summary
Clinical Daily Summary: What Happened on October 19, 2026
Gilead reports 23% placebo-adjusted remission rate for ulcerative colitis drug
Other clinical updates include interim ovarian cancer survival data, smell-loss trial results and a small lung cancer combination study.
Today in brief
Emvistegrast achieved a 23% placebo-adjusted clinical remission rate after 12 weeks in Gilead’s Phase 2 study of moderate to severe ulcerative colitis.1 Cyrano Therapeutics said CYR-064 met its Phase 2 safety endpoint, with efficacy signals among participants younger than 60.2 In OSE Immunotherapeutics’ 106-person Phase 2 lung cancer trial, one-year survival was higher with both Tedopi combinations than with chemotherapy alone.3
Zentalis reported interim median overall survival of 15.8 months for patients with Cyclin E1-positive ovarian cancer, versus 7.5 months for those without the marker.4
Also worth knowing
-
In Zentalis’ DENALI Part 1b study, retrospective testing classified 48 patients as Cyclin E1-positive and 46 as negative. Investigators reported no newly identified safety signals in the interim review.4
-
Among FLAVOR trial participants younger than 60, high-dose CYR-064 improved two patient-reported smell measures more than placebo over 24 weeks. No serious adverse events were linked to treatment, and overall adverse-event rates were similar between groups.2
-
Gilead executive Swati Tole said the company sees potential for emvistegrast as an oral ulcerative colitis treatment.1
-
Combi-TED had no Tedopi-only group, so it could not determine how much benefit came from adding docetaxel or nivolumab. OSE expects results from its separate Phase 3 ARTEMIA trial in early 2028.3
Also published
- Data reveal is promising for GSK's lung cancer drug ris-rez pharmaphorum
- Waiting to get sick enough Nature Medicine